Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today ...
Welcome to the new series of the House Guest podcast where C&TH Interiors Editor Carole Annett chats with experts from the ...